Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Sikiric, P; Seiwerth, S; Rucman, R; Turkovic, B; Rokotov, DS; Brcic, L; Sever, M; Klicek, R; Radic, B; Drmic, D; Ilic, S; Kolenc, D; Aralica, G; Stupnisek, M; Suran, J; Barisic, I; Dzidic, S; Vrcic, H; Sebecic, B.
Stable gastric pentadecapeptide BPC 157-NO-system relation.
Curr Pharm Des. 2014; 20(7): 1126-1135.
Doi: 10.2174/13816128113190990411
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Brcic Luka
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We reviewed stable gastric pentadecapeptide BPC 157-NO-system-relation, its close participation in Moncada's (maintained vascular integrity, platelets control) homeostatic healing response of NO-system to injury. Namely, BPC 157's particular healing effect also affects all events after vascular integrity loss (dependent on circumstances, it reduces either thrombosis (abdominal aorta anastomosis) or bleeding/thrombocytopenia (amputation, heparin, warfarin, aspirin)) and in a series of different injurious models, acute and chronic, BPC 157 consistently advances healing after severe injuries in various tissues spontaneously unable to heal; stimulates egr-1 and naB2 genes; exhibits high safety (LD1 not achieved)). Hypothesis, that BPC 157 (since formed constitutively in the gastric mucosa, stable in human gastric juice, along with significance of NO-synthase and the basal formation of NO in stomach mucosa, greater than that seen in other tissues) exhibits a general, effective competing both with L-arginine analogues (i. e., L-NAME) and L-arginine, and that this has some physiologic importance (NO-generation), later, practically supports its beneficial effects illustrating BPC 157 and NOsystem mutual (with L-NAME/L-arginine; alone and together) relations in (i) gastric mucosa and mucosal protection, following alcohol lesions, in cytoprotection course, NO-generation, and blood pressure regulation; (ii) alcohol acute/chronic intoxication, and withdrawal; (iii) cardiovascular disturbances, chronic heart failure, pulmonary hypertension, and arrhythmias; (iv) disturbances after hypokalemia and hyperkalemia, and potassium-cell membrane dysfunction; and finally, in (v) complex healing failure, proved by the fistulas healing, colocutaneous and esophagocutaneous. However, how this advantage of modulating NO-system (i. e., particular effect on eNOS gene), may be practically translated into an enhanced clinical performance remains to be determined.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Cardiovascular Diseases - drug therapy
- Disease Models, Animal -
- Gastric Mucosa - drug effects Gastric Mucosa - physiology Gastric Mucosa - physiopathology
- Humans -
- Nitric Oxide - metabolism
- Peptide Fragments - pharmacology Peptide Fragments - physiology Peptide Fragments - therapeutic use
- Proteins - pharmacology Proteins - physiology Proteins - therapeutic use
- Wound Healing - drug effects Wound Healing - physiology
- Find related publications in this database (Keywords)
- Arrhythmias
- Chronic Heart Failure
- Pentadecapeptide BPC 157
- Pulmonary Hypertension
- Thrombocytopenia
- Thrombosis